Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Pannaux

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
European Journal of Heart Failure|May 29, 2018
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysisMichel Komajda, Michael Böhm, Jeffrey S Borer, et al.
Statistics in Medicine|December 15, 2018
Predictive probability of success using surrogate endpointsGaelle Saint-Hilary, Valentine Barboux, Matthieu Pannaux, et al.
Statistics in Medicine|January 31, 2022
A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpointsFulvio Di Stefano, Matthieu Pannaux, Anne Correges, et al.
Journal of the American College of Cardiology|January 24, 2024
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial HypertensionEkkehard Grünig, Pavel Jansa, Fenling Fan, et al.
Advances in Therapy|March 13, 2026
Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label PeriodH James Ford, Kelly M Chin, Fenling Fan, et al.
Circulation. Heart Failure|June 26, 2020
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure StudyBenoît Tyl, José Lopez Sendon, Jeffrey S Borer, et al.
European Journal of Heart Failure|May 3, 2017
Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trialMichel Komajda, Richard Isnard, Alain Cohen-Solal, et al.
The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
European Journal of Heart Failure|May 29, 2018
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysisMichel Komajda, Michael Böhm, Jeffrey S Borer, et al.
Statistics in Medicine|December 15, 2018
Predictive probability of success using surrogate endpointsGaelle Saint-Hilary, Valentine Barboux, Matthieu Pannaux, et al.
Statistics in Medicine|January 31, 2022
A comparison of estimation methods adjusting for selection bias in adaptive enrichment designs with time-to-event endpointsFulvio Di Stefano, Matthieu Pannaux, Anne Correges, et al.
Journal of the American College of Cardiology|January 24, 2024
Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial HypertensionEkkehard Grünig, Pavel Jansa, Fenling Fan, et al.
Advances in Therapy|March 13, 2026
Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label PeriodH James Ford, Kelly M Chin, Fenling Fan, et al.
Circulation. Heart Failure|June 26, 2020
Comparison of Outcome Adjudication by Investigators and by a Central End Point Committee in Heart Failure Trials: Experience of the SHIFT Heart Failure StudyBenoît Tyl, José Lopez Sendon, Jeffrey S Borer, et al.
European Journal of Heart Failure|May 3, 2017
Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trialMichel Komajda, Richard Isnard, Alain Cohen-Solal, et al.
The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.
Pageof 1